Suspected Giant Cell Arteritis
Age 50 or over with new headache, jaw claudication, scalp tenderness, visual symptoms, PMR symptoms, or unexplained high ESR or CRP
All Pathways
OphthalmologyEmergency
Giant Cell Arteritis (GCA) and Arteritic AION Management
Giant Cell Arteritis (GCA) and Arteritic AION Management: Suspected Giant Cell Arteritis → Strong suspicion: start steroids today → Visual symptoms or s...
Pathway Overview
17 steps
Algorithm Steps
17 total
01Start 02Warning Strong suspicion: start steroids today
Do not wait for biopsy, ultrasound or blood results. Specialist review within 24 hours. Age under 50: GCA is very rare; seek specialist advice on other causes.
- Strongyloides risk (lived in or visited endemic areas overseas or in northern or central Australia): send serology and discuss empirical ivermectin with ID. Do not delay steroids.
- Diabetes: start a glucose plan with the first dose. Steroids raise glucose, mostly in the afternoon.
- Any visual symptom: emergency. Same-day ophthalmology.
03Decision Visual symptoms or signs?
Any: vision loss, amaurosis fugax, diplopia, RAPD, optic disc swelling or pallor, retinal artery occlusion
- If Yes
04Action Visual symptoms: IV methylprednisolone now
Threatened vision is an emergency. Admit. Vision can still worsen in the first days of treatment.
- Adult: IV methylprednisolone 500-1000 mg daily for 3 days (ACR 2021: 3-5 days)
- Then oral prednisolone 60 mg once daily (adult)
- Same-day ophthalmology review
- Do not delay treatment for biopsy or imaging
05Action Bloods: ideally before the first steroid dose
Do not delay steroids for results.
- ESR, CRP, FBC, UEC, LFT, glucose and HbA1c
- Normal ESR and CRP make GCA less likely but do not exclude it
- Before immunosuppression: hepatitis B, hepatitis C and HIV serology
- Strongyloides serology if at risk (see warning above)
06Warning Months of high-dose steroids: prevent infection
Plan in the first weeks. Do not delay steroids for these steps.
- PJP prophylaxis: consider if prednisolone is above 15-30 mg daily for more than 2-4 weeks (EULAR 2022)
- Before tocilizumab: screen for latent TB (IGRA), hepatitis B and hepatitis C
- Vaccines: give non-live vaccines. Live vaccines are contraindicated on immunosuppression.
07Action Confirm: temporal and axillary artery ultrasound
First-line test where an experienced ultrasound service exists (EULAR 2023). Do it early: steroids reduce the signs within days.
- Halo sign in temporal or axillary arteries supports GCA
- High suspicion and positive ultrasound: GCA confirmed without biopsy (EULAR, BSR)
- Ultrasound not available, negative or unclear: temporal artery biopsy
- Large-vessel involvement: CT or MR angiography, or PET-CT (ACR 2021)
08Action Temporal artery biopsy if ultrasound not conclusive
Preferred test in ACR 2021. Keep steroids going.
- Aim within 2 weeks of starting steroids
- Unilateral biopsy first; segment longer than 1 cm
- Negative biopsy does not exclude GCA: large-vessel imaging and specialist review (ACR 2021)
09Decision Symptoms resolving on steroids?
Headache and systemic symptoms usually improve within days
- If Yes
10Action Responding: specialist-led steroid taper
Taper to the lowest dose that controls disease. EULAR 2025 target: 15-20 mg daily by 2-3 months; aim to stop by 12-18 months.
- Example (BSR 2020): keep 40-60 mg until symptoms and ESR/CRP settle
- Then reduce by 10 mg every 2 weeks to 20 mg
- Then by 2.5 mg every 2-4 weeks to 10 mg
- Then by 1 mg every 1-2 months if no relapse
- Shorter taper when tocilizumab is used (specialist protocol)
11Action Steroid-sparing: tocilizumab (new or relapsing GCA)
Specialist decision. ACR 2021 suggests it with steroids for newly diagnosed GCA and for relapse.
- Adult: tocilizumab 162 mg SC once weekly with a steroid taper (every 2 weeks may be used)
- PBS Authority: rheumatologist, clinical immunologist or neurologist; maximum 52 weeks
- Do not start with active serious infection, ANC below 2 x 10^9/L or ALT/AST above 1.5 x ULN. Caution: platelets below 100 x 10^9/L; diverticulitis (perforation risk)
- Suppresses CRP and fever: infection can present late; judge flares clinically
- Monitor ALT/AST, neutrophils, platelets and lipids
- If tocilizumab is not suitable: methotrexate (off-label), once WEEKLY with folic acid; avoid in severe renal impairment; caution with trimethoprim-sulfamethoxazole
12Action Long-term: steroid harm and relapse
GCA needs long-term clinical follow-up (ACR 2021).
- Bone: calcium, vitamin D and a bone-protecting drug (prednisolone 30 mg or more daily for over 30 days means very high fracture risk)
- Relapse means new symptoms: specialist review, raise steroid dose, add or continue tocilizumab. Rising ESR/CRP alone: observe closely, do not escalate (ACR 2021)
- Check glucose, BP and weight at each visit
- Aspirin: do not add for GCA alone; add for critical or flow-limiting carotid or vertebral disease (ACR 2021). Keep aspirin taken for another reason
- Aortic aneurysm risk: ask about symptoms; imaging as the specialist advises. Adrenal insufficiency risk as the dose falls to low levels after long use
13Decision Sustained remission on taper?
No symptoms of GCA while the steroid dose falls
- If Yes
14Outcome Remission: taper off steroids, keep monitoring
ACR 2021 prefers tapering off over long-term low-dose steroids. Watch for relapse.
If No15Outcome Relapse or refractory: rheumatology-led care
Add or change steroid-sparing therapy. Consider large-vessel imaging.
If No16Action Not responding: review diagnosis urgently
Poor response is unusual in GCA. Rheumatology review the same week.
- Reconsider the diagnosis: infection, cancer, other vasculitis, non-arteritic ION
- Check adherence and the dose taken
- New or worse visual symptoms: emergency ophthalmology and IV methylprednisolone
- Confirmed GCA: add a steroid-sparing drug (next step)
- Path rejoins step 11Shared downstream outcome
If No17Action No visual symptoms: oral prednisolone now
Strong suspicion: start today, before test results. Then the same steps as the visual branch: bloods, infection prevention, ultrasound or biopsy, and taper.
- Adult: prednisolone 40-60 mg once daily (EULAR 2025)
- Give daily, not on alternate days (ACR 2021)
- Refer to rheumatology or a GCA fast-track clinic within 24 hours (EULAR 2025)
- New visual symptoms at any time: treat as the visual emergency
- Path rejoins step 05Shared downstream outcome
Guideline Source
2021 ACR/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis
Clinical Safety Information
Clinical Decision Support — Not a Substitute for Clinical Judgment
Individual patient factors may require deviation from these recommendations.
Known Limitations
- Specialist-led condition: steroid-sparing therapy and taper need rheumatology input.
- Tocilizumab suppresses CRP and fever, so infection and flare can be missed.
- Large-vessel GCA and Takayasu arteritis are covered only briefly.
- Taper shown is one example (BSR 2020); EULAR 2025 and local protocols may differ.
Contraindicated Populations
Children and adults under 50 years (GCA is very rare; consider other diagnoses)
Applicable Regions
USEUAUGlobal
AU: Tocilizumab SC is TGA-registered for GCA and PBS-listed (Authority; specialist; max 52 weeks). Upadacitinib is not TGA-registered for GCA (PI Jan 2026). Screen for Strongyloides if lived in or visited endemic areas, including northern and central Australia.
EU: EULAR 2025 PMR/LVV management recommendations; EULAR 2023 imaging (ultrasound first-line, include axillary arteries); BSR 2020 GCA guideline.
US: ACR/VF 2021 guideline is current. Temporal artery biopsy preferred over ultrasound. Tocilizumab and upadacitinib FDA-approved for GCA.
Global: Same principles: steroids without delay, specialist review within 24 hours, confirm by ultrasound or biopsy.
Version 2Next review: 2027-09-30
Next steps
Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.
Related Resources
Frequently Asked Questions
What is the Giant Cell Arteritis (GCA) and Arteritic AION Management?
The Giant Cell Arteritis (GCA) and Arteritic AION Management is a emergency clinical algorithm for Ophthalmology. It provides a structured decision tree to guide clinical decision-making, based on 2021 ACR/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis.
What guideline is the Giant Cell Arteritis (GCA) and Arteritic AION Management based on?
This algorithm is based on 2021 ACR/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis (DOI: 10.1002/art.41774).
What are the limitations of the Giant Cell Arteritis (GCA) and Arteritic AION Management?
Known limitations include: Specialist-led condition: steroid-sparing therapy and taper need rheumatology input.; Tocilizumab suppresses CRP and fever, so infection and flare can be missed.; Large-vessel GCA and Takayasu arteritis are covered only briefly.; Taper shown is one example (BSR 2020); EULAR 2025 and local protocols may differ.. Individual patient factors may require deviation from these recommendations.
Get AI-Powered Analysis Alongside This Algorithm
In AttendMe.ai, the Giant Cell Arteritis (GCA) and Arteritic AION Management appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.
Try AttendMe Free